siRNAs: their potential as therapeutic agents - Part II. Methods of delivery

Sunit Kumar Singh; Praveensingh B. Hajeri

doi:10.1016/j.drudis.2009.06.002

siRNAs: their potential as therapeutic agents - Part II. Methods of delivery

Sunit Kumar Singh, Praveensingh B. Hajeri

Surgery

Research output: Contribution to journal › Review article › peer-review

30 Scopus citations

Abstract

RNA interference (RNAi) is a sequence-specific mechanism to control the expression of target genes. This technique has proven potentials both in vivo and in vitro. The main hurdle for using RNAi-based therapy is the effective delivery of RNAi-based drugs to the target cells or tissues in vivo. The aspects of off-target effects, delivery methods, induction of immune response and dose determination for delivery should, however, be considered carefully. If these challenges associated with siRNA can be met, then the potentials of RNAi could be exploited to the full for the development of therapeutic tools and drugs.

Original language	English (US)
Pages (from-to)	859-865
Number of pages	7
Journal	Drug Discovery Today
Volume	14
Issue number	17-18
DOIs	https://doi.org/10.1016/j.drudis.2009.06.002
State	Published - Sep 2009

Bibliographical note

Funding Information:
Authors are highly thankful to Dr Lalji Singh, Director, Centre for Cellular & Molecular Biology (CCMB), Hyderabad for providing all the necessary support during the preparation of this manuscript. The financial support (Ref: BT/PR10709/AGR/36/598/2008) from the Department of Biotechnology (DBT), Govt. of India, New Delhi is highly acknowledged.

Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.drudis.2009.06.002

Find It

Find It at U of M Libraries

Cite this

@article{0befad15c84f4f779d8d33f5cbc13e09,

title = "siRNAs: their potential as therapeutic agents - Part II. Methods of delivery",

abstract = "RNA interference (RNAi) is a sequence-specific mechanism to control the expression of target genes. This technique has proven potentials both in vivo and in vitro. The main hurdle for using RNAi-based therapy is the effective delivery of RNAi-based drugs to the target cells or tissues in vivo. The aspects of off-target effects, delivery methods, induction of immune response and dose determination for delivery should, however, be considered carefully. If these challenges associated with siRNA can be met, then the potentials of RNAi could be exploited to the full for the development of therapeutic tools and drugs.",

author = "Singh, {Sunit Kumar} and Hajeri, {Praveensingh B.}",

note = "Funding Information: Authors are highly thankful to Dr Lalji Singh, Director, Centre for Cellular & Molecular Biology (CCMB), Hyderabad for providing all the necessary support during the preparation of this manuscript. The financial support (Ref: BT/PR10709/AGR/36/598/2008) from the Department of Biotechnology (DBT), Govt. of India, New Delhi is highly acknowledged. Copyright: Copyright 2009 Elsevier B.V., All rights reserved.",

year = "2009",

month = sep,

doi = "10.1016/j.drudis.2009.06.002",

language = "English (US)",

volume = "14",

pages = "859--865",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd",

number = "17-18",

}

TY - JOUR

T1 - siRNAs

T2 - their potential as therapeutic agents - Part II. Methods of delivery

AU - Singh, Sunit Kumar

AU - Hajeri, Praveensingh B.

N1 - Funding Information: Authors are highly thankful to Dr Lalji Singh, Director, Centre for Cellular & Molecular Biology (CCMB), Hyderabad for providing all the necessary support during the preparation of this manuscript. The financial support (Ref: BT/PR10709/AGR/36/598/2008) from the Department of Biotechnology (DBT), Govt. of India, New Delhi is highly acknowledged. Copyright: Copyright 2009 Elsevier B.V., All rights reserved.

PY - 2009/9

Y1 - 2009/9

N2 - RNA interference (RNAi) is a sequence-specific mechanism to control the expression of target genes. This technique has proven potentials both in vivo and in vitro. The main hurdle for using RNAi-based therapy is the effective delivery of RNAi-based drugs to the target cells or tissues in vivo. The aspects of off-target effects, delivery methods, induction of immune response and dose determination for delivery should, however, be considered carefully. If these challenges associated with siRNA can be met, then the potentials of RNAi could be exploited to the full for the development of therapeutic tools and drugs.

AB - RNA interference (RNAi) is a sequence-specific mechanism to control the expression of target genes. This technique has proven potentials both in vivo and in vitro. The main hurdle for using RNAi-based therapy is the effective delivery of RNAi-based drugs to the target cells or tissues in vivo. The aspects of off-target effects, delivery methods, induction of immune response and dose determination for delivery should, however, be considered carefully. If these challenges associated with siRNA can be met, then the potentials of RNAi could be exploited to the full for the development of therapeutic tools and drugs.

UR - http://www.scopus.com/inward/record.url?scp=69549119978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549119978&partnerID=8YFLogxK

U2 - 10.1016/j.drudis.2009.06.002

DO - 10.1016/j.drudis.2009.06.002

M3 - Review article

C2 - 19540929

AN - SCOPUS:69549119978

SN - 1359-6446

VL - 14

SP - 859

EP - 865

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 17-18

ER -

siRNAs: their potential as therapeutic agents - Part II. Methods of delivery

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this